Prevention and correction of alpelisib-induced hyperglycemia (view of endocrinologist)
https://doi.org/10.33667/2078-5631-2022-13-44-47
Abstract
Alpelisib is a modern targeted drug for the treatment of patients with hormone receptor-positive HER2-negative metastatic breast cancer with a PIK3CA gene mutation. Blockade of PI3K can significantly increase progression-free survival, however, it is accompanied by adverse events, the most common of which is hyperglycemia. The article presents recommendations for risk estimation, prevention and correction of alpelisibinduced hyperglycemia.
About the Author
I. M. Kovalenko
National Medical Research Centre of Oncology n. a. N. N. Petrov
Russian Federation
Russian Federation
Kovalenko Irina M., PhD Med, endocrinologist, researcher at Scientific Laboratory of Subcellular Technologies with a Group of Oncoendocrinilogy
Saint Petersburg
References
1. Sokolova T.N., Aleksakhina S.N., Janus G.A. Frequency and spectrum of PIK3CA mutations in hormone-dependent HER2-negative advanced breast cancer in Russian patients. Modern Oncology. 2021. V. 23, No. 1. P. 61–67. DOI: 10.26442/18151434.2021.1.200744.
2. Semiglazova T. Yu., Semiglazov V. V., Klimenko V. V. Alpelisib for the treatment of HR+ HER2-metastatic breast cancer in patients with PIK3CA mutation: results of the SOLAR-1 study. Pharmateka. 2020. V. 27, No. 7. P. 15–23. DOI: 10.18565/pharmateca.2020.7.15–23.
3. Instructions for medical use of the drug Picray LP-006279 dated 06/19/2020.
4. Rugo H.S., André F., Yamashita T. et al. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer. Ann. Oncol. 2020. Vol. 31 (8). P. 1001–1010. DOI: 10.1016/j.annonc.2020.05.001.
5. Tankova T., Senkus E., Beloyartseva M. et al. Management Strategies for Hyperglycemia Associated with the α-Selective PI3K Inhibitor Alpelisib for the Treatment of Breast Cancer. Cancers. 2022. Vol. 14 (1598). https://doi.org/10.3390/cancers14071598
6. Mazurina N.V., Artamonova E.V., Beloyartseva M.F. Consensus on the prevention and correction of hyperglycemia in patients receiving therapy with alpelisib. Modern Oncology. 2020. V. 22, No. 4. P. 56–59.
7. Leto D., Saltiel A.R. Regulation of glucose transport by insulin: traffic control of GLUT4. Nat. Rev. Mol. Cell Biol. 2012. Vol. 13 (6). Р. 383–396.
8. Świderska E., Strycharz J., Wróblewski A. et al. Role of PI3K/AKT Pathway in Insulin-Mediated Glucose Uptake. 2018. DOI: http://dx.doi.org/10.5772/intechopen.80402
9. Rodоn J., Demanse D., Hope S. et al. Pooled analysis of X2101 and SOLAR-1: A risk analysis of ALP-induced HG using baseline factors in patients with advanced solid tumors and BC. ESMO-BC May 8, 2021.
10. Dedov I.I., Shestakov M.V., Maiorov A. Yu. Algorithms of specialized medical care for patients with diabetes mellitus. 10th issue. M. 2021. DOI: 10.14341/DM12802.
11. Filonenko D., Zhukova L. Prophylactic use of metformin in patients on alpelisib treatment. Journal of Clinical Oncology. 2022. Vol. 40 (16). Р. 13040. DOI: 10.1200/JCO.2022.40.16_suppl.e13040.
12. Rugo H.S., Lacouture M.E., Goncalves M.D. et al. A multidisciplinary approach to optimizing care of patients treated with alpelisib. The Breast. 2022. Vol. 61. P. 156–167. https://doi.org/10.1016/j.breast.2021.12.016
13. Lu Y., Chiu J., Airoldi M. et al. Sodium glucose cotransporter 2 (SGLT2) inhibitors for alpelisib-induced hyperglycemia: a report of 6 cases from SOLAR-1. Presented at the European Society for Medical Oncology Virtual Congress 2020; 19–21 September 2020.
14. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021. Vol. 44 (1). Р. 111–124. https://doi.org/10.2337/dc21-S009.
15. WHO. Global strategy on diet, physical activity and health. Geneva, World Health Organization (WHO). 2004. P. 19. https://www.who.int/publications/i/item/9241592222
Review
For citations:
Kovalenko I.M. Prevention and correction of alpelisib-induced hyperglycemia (view of endocrinologist). Medical alphabet. 2022;(13):44-47. (In Russ.) https://doi.org/10.33667/2078-5631-2022-13-44-47
Views:
463
Email this article 